Yorkshire medical consultancy expands into Europe with launch of Italian subsidiary and office

Yorkshire headquartered drug and medical device regulatory affairs consultancy, Woodley BioReg, is celebrating the launch of its new Italian subsidiary, Woodley BioReg Srl.

Based in the northern Italian city of Milan, this office will serve to fortify Woodley BioReg’s access to the European market, opening up new avenues and routes to market for clients using its consulting and import services.

This will significantly enhance the level of services Woodley BioReg can offer its non-EU clients, particularly those based in South Asia and Asia-Pacific regions.

The decision to base the subsidiary in Italy over other member states is due to the country being a founding member state of the union and as such the regulatory body, the Italian Medicines Agency (AIFA), is well established and “extremely active” in European regulatory affairs.

AIFA continues to be a key contributor to the European Medicine Agency (EMA) and Woodley BioReg has had a number of positive interactions with the Italian regulatory agency in relation to legislation for both pharmaceutical and biopharmaceutical products.

Managing director and principal regulatory consultant at Woodley BioReg, Dr. Ash Ramzan, commented: “We want to provide a seamless experience for our clients looking to bring their products to the European market, and therefore it’s imperative that we have our own base in the EU to facilitate that.

“We’re extremely excited to begin operations in Italy, which will start with immediate effect, and have the utmost respect for those operating in the healthcare industry there. We’re particularly looking forward to working more closely with the experts at AIFA, as their reputation precedes them.”

Our Partners